Retatrutide vs Semaglutide: What TRANSCEND-T2D-2 Reported on 28 October 2026

What Did Lilly Report From TRANSCEND-T2D-2?

On 28 October 2026 Eli Lilly announced positive topline results from TRANSCEND-T2D-2, which it describes as the first Phase 3 trial to compare its investigational triple agonist retatrutide (LY3437943) directly with another incretin-based drug, here injectable semaglutide at 2 mg, the highest dose approved for that product.[1] The trial is registered as NCT06260722 and enrolled adults with type 2 diabetes whose glycaemic control was inadequate on metformin with or without an SGLT2 inhibitor; the registered primary outcome is change in HbA1c at week 80.[2]

Per Lilly and trade-press summaries, both retatrutide doses lowered A1C by an average of 2.2 percentage points against 1.8 for semaglutide 2 mg, with the primary objective being non-inferiority of the 12 mg dose, which was also reported as superior (P < .001).[1][3] Body-weight change, a key secondary endpoint, was reported as 19.5% to 20.9% for retatrutide versus 9.4% for semaglutide, with both retatrutide doses superior under family-wise type I error control.[3][4] Lilly also said improvements were seen in non-HDL cholesterol, triglycerides and systolic blood pressure but gave no numerical effect sizes in the topline.[3]

What Did the Trial Report on Tolerability and Discontinuation?

Discontinuation due to adverse events was reported at 4.8% to 7.9% across the retatrutide arms versus 2.7% with semaglutide.[3] That is a higher rate in the investigational arms, and a topline percentage cannot show which events drove it. For the adverse-event picture in earlier trials, see our summaries of reported adverse events in the retatrutide literature and the TRIUMPH-2 safety paper. Researchers should wait for the full dataset before drawing conclusions about tolerability.

Lilly also said an extension in which about 650 participants continue retatrutide for a further 24 weeks is planned to assess longer-term efficacy and safety.[1]

How Should Researchers Read a Topline Head-to-Head Result?

With caution, for four reasons. First, it is sponsor-reported and unreviewed; the estimand (for example, treatment-regimen versus efficacy estimand) strongly affects headline figures, and Lilly's release and later journal tables can differ. Second, the comparator is a single semaglutide dose in a single population, adults with type 2 diabetes on background therapy, so it says little about other populations or comparators. Third, the 80-week design means durability beyond that point is unaddressed. Fourth, a randomised comparison against one drug is not a mechanistic explanation of why outcomes differ.

That last point is where laboratory pharmacology comes in. Retatrutide acts on GIP, GLP-1 and glucagon receptors; semaglutide acts on the GLP-1 receptor alone. Receptor-level questions such as relative potency, biased signalling and cross-receptor effects are studied in vitro, not inferred from trial arms. Our retatrutide mechanism of action guide summarises the published receptor pharmacology, and retatrutide vs Ozempic collects the earlier comparative material.

Is Retatrutide Approved, and What Happens Next?

No. Retatrutide has no marketing authorisation from the FDA, MHRA or any regulator. Lilly's third-quarter 2026 release, published on 29 October, highlighted this head-to-head result, and earlier company statements put a US submission in the first quarter of 2027.[5] The legal dispute over how the FDA classifies retatrutide is separate and unresolved in our reporting; see the classification lawsuit and the filing timeline. Watch for a conference presentation or journal publication of TRANSCEND-T2D-2, which would supply the missing tables.

How Does Licensed Pharma Development Differ From Research-Use Compounds?

TRANSCEND-T2D-2 is a regulated clinical programme: a licensed pharmaceutical sponsor, a registered protocol, ethics oversight and medical supervision of participants. Nothing in its results transfers to a laboratory reagent. Velox Peptides supplies retatrutide solely as an HPLC-verified in vitro research reagent, with no therapeutic claims, and we report trial news only as third-party information for researchers. For compound specifications see the research-grade retatrutide page.

This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions